Background The available evidence on the benefits and harms of novel drugs and therapeutic biologics at the time of approval is reported in publicly available documents provided by the US Food and Drug Administration (FDA). We aimed to create a comprehensive database providing the relevant information required to systematically analyze and assess this early evidence in meta-epidemiological research. Methods We designed a modular and flexible database of systematically collected data. We identified all novel cancer drugs and therapeutic biologics approved by the FDA between 2000 and 2016, recorded regulatory characteristics, acquired the corresponding FDA approval documents, identified all clinical trials reported therein, and extracted tri...
International audienceBackground: Oncology is among the most active therapeutic fields in terms of n...
Regulatory agencies around the world have been using flexible requirements for approval of new drugs...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
Abstract Background The available evidence on the benefits and harms of novel drugs and therapeutic ...
International audienceBackground: The available evidence on the benefits and harms of novel drugs an...
The available evidence on the benefits and harms of novel drugs and therapeutic biologics at the tim...
The US Food and Drug Administration (FDA) approves novel drugs that appear to be effective for their...
International audienceIMPORTANCE: Clinical trial evidence used to support drug approval is typically...
Importance: Clinical trial evidence used to support drug approval is typically the only information ...
Background: major clinical outcomes of anticancer drugs may differ between clinical trials and clini...
Purpose: Real-World Data (RWD) studies are increasingly used to support regulatory approvals, reimbu...
ImportanceAlthough several cancer drugs receive US Food and Drug Administration (FDA) approval each ...
Background: Advances in cancer medicines have resulted in tangible health impacts, but the magnitude...
To achieve therapeutic innovation in oncology, already expensive novel medicines are often concomita...
International audienceBackground: Oncology is among the most active therapeutic fields in terms of n...
Regulatory agencies around the world have been using flexible requirements for approval of new drugs...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
Abstract Background The available evidence on the benefits and harms of novel drugs and therapeutic ...
International audienceBackground: The available evidence on the benefits and harms of novel drugs an...
The available evidence on the benefits and harms of novel drugs and therapeutic biologics at the tim...
The US Food and Drug Administration (FDA) approves novel drugs that appear to be effective for their...
International audienceIMPORTANCE: Clinical trial evidence used to support drug approval is typically...
Importance: Clinical trial evidence used to support drug approval is typically the only information ...
Background: major clinical outcomes of anticancer drugs may differ between clinical trials and clini...
Purpose: Real-World Data (RWD) studies are increasingly used to support regulatory approvals, reimbu...
ImportanceAlthough several cancer drugs receive US Food and Drug Administration (FDA) approval each ...
Background: Advances in cancer medicines have resulted in tangible health impacts, but the magnitude...
To achieve therapeutic innovation in oncology, already expensive novel medicines are often concomita...
International audienceBackground: Oncology is among the most active therapeutic fields in terms of n...
Regulatory agencies around the world have been using flexible requirements for approval of new drugs...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...